β-amyloid and cholinergic neurons

Neurochemical Research

Volumn 28, Issue 3-4, 2003, Pages 499-506

  Doležal, Vladimír ^a   Kašparová, Jana ^a  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

amyloid; Acetylcholine; Alzheimer's disease; Cholinergic neurons; Cholinergic phenotype; Glucose metabolism

Indexed keywords

AMYLOID BETA PROTEIN; PEPTIDE;

ALZHEIMER DISEASE; ARTICLE; ATROPHY; BIOCHEMISTRY; CHOLINERGIC NERVE CELL; COGNITION; GENE MUTATION; GENETIC DISORDER; NERVE CELL DEGENERATION; NERVE DEGENERATION; PRIORITY JOURNAL;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CHOLINERGIC FIBERS; GLUCOSE; HUMANS; NEURONS; PHENOTYPE;

EID: 0037375486     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022865121743     Document Type: Article

References (141)

1. Selkoe, D. J. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741-766.
2. Saitoh, T., Sundsmo, M., Roch, J. M., Kimura, N., Cole, G., Schubert, D., Oltersdorf, T., and Schenk, D. B. 1989. Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. Cell 58:615-622.
3. Schubert, D., Jin, L. W., Saitoh, T., and Cole, G. 1989. The regulation of amyloid beta protein precursor secretion and its modulatory role in cell adhesion. Neuron 3:689-694.
4. Breen, K. C., Bruce, M., and Anderton, B. H. 1991. Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion. J. Neurosci. Res. 28:90-100.
5. Chen, M. and Yankner, B. A. 1991. An antibody to beta amyloid and the amyloid precursor protein inhibits cell-substratum adhesion in many mammalian cell types. Neurosci. Lett. 125:223-226.
6. Milward, E. A., Papadopoulos, R., Fuller, S. J., Moir, R. D., Small, D., Beyreuther, K., and Masters, C. L. 1992. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 9:129-137.
7. Mattson, M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I., and Rydel, R. E. 1993. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10:243-54.
8. Clarris, H. J., Nurcombe, V., Small, D. H., Beyreuther, K., and Masters, C. L. 1994. Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants. J. Neurosci. Res. 38:248-258.
9. Qiu, W. Q., Ferreira, A., Miller, C., Koo, E. H., and Selkoe, D. J. 1995. Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. J. Neurosci. 15:2157-2167.
10. Coulson, E. J., Barrett, G. L., Storey, E., Bartlett, P. F., Beyreuther, K., and Masters, C. L. 1997. Down-regulation of the amyloid protein precursor of Alzheimer's disease by anti-sense oligonucleotides reduces neuronal adhesion to specific substrata. Brain Res. 770:72-80.
11. Gillian, A. M., McFarlane, I., Lucy, F. M., Overly, C., McConlogue, L., and Breen, K. C. 1997. Individual isoforms of the amyloid beta precursor protein demonstrate differential adhesive potentials to constituents of the extracellular matrix. J. Neurosci. Res. 49:154-160.
12. Mattson, M. P. 1997. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77:1081-1132.
13. Perez, R. G., Zheng, H., Van der Ploeg, L. H., and Koo, E. H. 1997. The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J. Neurosci. 17:9407-9414.
14. Sudo, H., Jiang, H., Yasukawa, T., Hashimoto, Y., Niikura, T., Kawasumi, M., Matsuda, S., Takeuchi, Y., Aiso, S., Matsuoka, M., Murayama, Y., and Nishimoto, I. 2000. Antibody-regulated neurotoxic function of cell-surface beta-amyloid precursor protein. Mol. Cell Neurosci. 16:708-723.
15. Zheng, H., Jiang, M., Trumbauer, M. E., Sirinathsinghji, D. J., Hopkins, R., Smith, D. W., Heavens, R. P., Dawson, G. R., Boyce, S., Conner, M. W., et al. 1995. Beta-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81:525-531.
16. White, A. R., Zheng, H., Galatis, D., Maher, F., Hesse, L., Multhaup, G., Beyreuther, K., Masters, C. L., and Cappai, R. 1998. Survival of cultured neurons from amyloid precursor protein knock-out mice against Alzheimer's amyloid-beta toxicity and oxidative stress. J. Neurosci. 18:6207-6217.
17. White, A. R., Multhaup, G., Maher, F., Bellingham, S., Camakaris, J., Zheng, H., Bush, A. I., Beyreuther, K., Masters, C. L., and Cappai, R. 1999. The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J. Neurosci. 19:9170-9179.
18. Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. 1992. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359:322-325.
19. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., et al. 1992. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359:325-327.
20. Vigo-Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., and Schenk, D. B. 1993. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61:1965-1968.
21. Furukawa, K., Sopher, B. L., Rydel, R. E., Begley, J. G., Pham, D.G., Martin, G. M., Fox, M., and Mattson, M. P. 1996. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 67:1882-1896.
22. Mattson, M. P., Guo, Z. H., and Geiger, J. D. 1999. Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. J. Neurochem. 73:532-537.
23. Whitson, J. S., Selkoe, D. J., and Cotman, C. W. 1989. Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science 243:1488-1490.
24. Whitson, J. S., Glabe, C. G., Shintani, E., Abcar, A., and Cotman, C. W. 1990. Beta-amyloid protein promotes neuritic branching in hippocampal cultures. Neurosci. Lett. 110:319-324.
25. Yankner, B. A., Duffy, L. K., and Kirschner, D. A. 1990. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science 250:279-282.
26. Pike, C. J., Walencewicz, A. J., Glabe, C. G., and Cotman, C. W. 1991. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563:311-314.
27. Beyreuther, K., Bush, A. I., Dyrks, T., Hilbich, C., Konig, G., Monning, U., Multhaup, G., Prior, R., Rumble, B., Schubert, W., et al. 1991. Mechanisms of amyloid deposition in Alzheimer's disease. Ann. N.Y. Acad. Sci. 640:129-139.
28. Sandbrink, R. and Beyreuther, K. 1996. Unraveling the molecular pathway of Alzheimer's disease: Research about presenilins gathers momentum. Mol. Psychiatry 1:438-444.
29. Sandbrink, R., Hartmann, T., Masters, C. L., and Beyreuther, K. 1996. Genes contributing to Alzheimer's disease. Mol. Psychiatry 1:27-40.
30. Mills, J. and Reiner, P. B. 1999. Regulation of amyloid precursor protein cleavage. J. Neurochem. 72:443-460.
31. Selkoe, D. J. 1999. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:A23-A31.
32. Small, D. H. and McLean, C. A. 1999. Alzheimer's disease and the amyloid beta protein: What is the role of amyloid? J. Neurochem. 73:443-449.
33. Fassbender, K., Masters, C., and Beyreuther, K. 2001. Alzheimer's disease: Molecular concepts and therapeutic targets. Naturwissenschaften 88:261-267.
34. Bradbury, J. 2001. Proteolysis problems implicated in neurodegenerative diseases. Lancet 357:1679.
35. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H. J., and Saido, T. C. 2001. Metabolic regulation of brain Abeta by neprilysin. Science 292:1550-1552.
36. Kurochkin, I. V. 2001. Insulin-degrading enzyme: Embarking on amyloid destruction. Trends Biochem. Sci. 26:421-425.
37. Selkoe, D. J. 2001. Clearing the brain's amyloid cobwebs. Neuron 32:177-180.
38. Shirotani, K., Tsubuki, S., Iwata, N., Takaki, Y., Harigaya, W., Maruyama, K., Kiryu-Seo, S., Kiyama, H., Iwata, H., Tomita, T., Iwatsubo, T., and Saido, T. C. 2001. Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J. Biol. Chem. 276:21895-21901.
39. Carson, J. A. and Turner, A. J. 2002. Beta-amyloid catabolism: Roles for neprilysin (NEP) and other metallopeptidases? J. Neurochem. 81:1-8.
40. Hoyer, S. 2000. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease: Causes and consequences: an update. Exp. Gerontol. 35:1363-1372.
41. Joseph, J., Shukitt-Hale, B., Denisova, N. A., Martin, A., Perry, G., and Smith, M. A. 2001. Copernicus revisited: Amyloid beta in Alzheimer's disease. Neurobiol. Aging 22:131-146.
42. Conway, K. A., Harper, J. D., and Lansbury, P. T., Jr. 2000. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39:2552-2563.
43. Haass, C. and Steiner, H. 2001. Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat. Neurosci. 4:859-860.
44. Klein, W. L., Krafft, G. A., and Finch, C. E. 2001. Targeting small Abeta oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci. 24:219-224.
45. Cuajungco, M. P., Goldstein, L. E., Nunomura, A., Smith, M. A., Lim, J. T., Atwood, C. S., Huang, X., Farrag, Y. W., Perry, G., and Bush, A. I. 2000. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J. Biol. Chem. 275:19439-19442.
46. Heininger, K. 2000. A unifying hypothesis of Alzheimer's disease: IV. Causation and sequence of events. Rev. Neurosci. 11 (Spec No.):213-328.
47. Saunders, A. M., Strittmatter, W. J., Schmechel, D., George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467-1472.
48. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
49. Strittmatter, W. J., Weisgraber, K. H., Goedert, M., Saunders, A. M., Huang, D., Corder, E. H., Dong, L. M., Jakes, R., Alberts, M. J., Gilbert, J. R., et al. 1994. Hypothesis: Microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp. Neurol. 125:163-671; discussion 172-174.
50. Oron, L., Efrati, M., and Michaelson, D. M. 2000. Secretion of the amyloid precursor protein is elevated isoform specifically by apolipoprotein E4. J. Neural Transm. (Suppl.) 59:163-169.
51. Sabo, T., Lomnitski, L., Nyska, A., Beni, S., Maronpot, R. R., Shohami, E., Roses, A. D., and Michaelson, D. M. 2000. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: The allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience 101:879-884.
52. Bodovitz, S. and Klein, W. L. 1996. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271:4436-4440.
53. Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., and Simons, K. 1998. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95:6460-6464.
54. Frears, E. R., Stephens, D. J., Walters, C. E., Davies, H., and Austen, B. M. 1999. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10:1699-1705.
55. Refolo, L. M., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., Duff, K., and Pappolla, M. A. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7:321-331.
56. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., Runz, H., Kuhl, S., Bertsch, T., von Bergmann, K., Hennerici, M., Beyreuther, K., and Hartmann, T. 2001. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98:5856-5861.
57. Kojro, E., Gimpl, G., Lammich, S., Marz, W., and Fahrenholz, F. 2001. From the cover: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. USA 98:5815-5820.
58. Hartmann, T. 2001. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci. 24:S45-S48.
59. Refolo, L. M., Pappolla, M. A., LaFrancois, J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., Tint, G. S., Wang, R., Mercken, M., Petanceska, S. S., and Duff, K. E. 2001. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8:890-899.
60. Runz, H., Rietdorf, J., Tomic, I., de Bernard, M., Beyreuther, K., Pepperkok, R., and Hartmann, T. 2002. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J. Neurosci. 22:1679-1689.
61. Wahrle, S., Das, P., Nyborg, A. C., McLendon, C., Shoji, M., Kawarabayashi, T., Younkin, L. H., Younkin, S. G., and Golde, T. E. 2002. Cholesterol -dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9:11-23.
62. Jarvik, G. P., Wijsman, E. M., Kukull, W. A., Schellenberg, G. D., Yu, C., and Larson, E. B. 1995. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: A case-control study. Neurology 45:1092-1096.
63. Notkola, I. L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., and Nissinen, A. 1998. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17:14-20.
64. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A. 2000. Statins and the risk of dementia. Lancet 356:1627-1631.
65. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and Siegel, G. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57:1439-1443.
66. Buxbaum, J. D., Oishi, M., Chen, H. I., Pinkas-Kramarski, R., Jaffe, E. A., Gandy, S. E., and Greengard, P. 1992. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA 89:10075-10078.
67. Nitsch, R. M., Slack, B. E., Wurtman, R. J., and Growdon, J. H. 1992. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-307.
68. Slack, B. E., Breu, J., Petryniak, M. A., Srivastava, K., and Wurtman, R. J. 1995. Tyrosine phosphorylation-dependent stimulation of amyloid precursor protein secretion by the M3 muscarinic acetylcholine receptor. J. Biol. Chem. 270:8337-8344.
69. Wolf, B. A., Wertkin, A. M., Jolly, Y. C., Yasuda, R. P., Wolfe, B. B., Konrad, R. J., Manning, D., Ravi, S., Williamson, J. R., and Lee, V. M. 1995. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J. Biol. Chem. 270:4916-4922.
70. Nitsch, R. M. 1996. From acetylcholine to amyloid: Neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration 5:477-482.
71. Nitsch, R. M., Deng, M., Growdon, J. H., and Wurtman, R. J. 1996. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J. Biol. Chem. 271:4188-4194.
72. Nitsch, R. M., Wurtman, R. J., and Growdon, J. H. 1996. Regulation of APP processing: Potential for the therapeutical reduction of brain amyloid burden. Ann. N.Y. Acad. Sci. 777:175-182.
73. Buxbaum, J. D., Gandy, S. E., Cicchetti, P., Ehrlich, M. E., Czernik, A. J., Fracasso, R. P., Ramabhadran, T. V., Unterbeck, A. J., and Greengard, P. 1990. Processing of Alzheimer beta/A4 amyloid precursor protein: Modulation by agents that regulate protein phosphorylation. Proc. Natl. Acad. Sci. USA 87:6003-6006.
74. McLaughlin, M. and Breen, K. C. 1999. Protein kinase C activation potentiates the rapid secretion of the amyloid precursor protein from rat cortical synaptosomes. J. Neurochem. 72:273-281.
75. Petryniak, M. A., Wurtman, R. J., and Slack, B. E. 1996. Elevated intracellular calcium concentration increases secretory processing of the amyloid precursor protein by a tyrosine phosphorylation-dependent mechanism. Biochem. J. 320(Pt 3):957-963.
76. Kim, S. H., Kim, Y. K., Jeong, S. J., Haass, C., Kim, Y. H., and Suh, Y. H. 1997. Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. Mol. Pharmacol. 52:430-436.
77. Hernandez, D., Sugaya, K., Qu, T., McGowan, E., Duff, K., and McKinney, M. 2001. Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport 12:1377-1384.
78. Isacson, O., Seo, H., Lin, L., Albeck, D., and Granholm, A. C. 2002. Alzheimer's disease and Down's syndrome: Roles of APP, trophic factors and ACh. Trends Neurosci. 25:79-84.
79. Yankner, B. A. 1996. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16:921-932.
80. Berlett, B. S. and Stadtman, E. R. 1997. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 272:20313-20316.
81. Finkel, T. and Holbrook, N. J. 2000. Oxidants, oxidative stress and the biology of ageing. Nature 408:239-247.
82. Miranda, S., Opazo, C., Larrondo, L. F., Munoz, F. J., Ruiz, F., Leighton, F., and Inestrosa, N. C. 2000. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog. Neurobiol. 62:633-648.
83. Pratico, D. and Delanty, N. 2000. Oxidative injury in diseases of the central nervous system: Focus on Alzheimer's disease. Am. J. Med. 109:577-585.
84. Arispe, N., Rojas, E., and Pollard, H. B. 1993. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. USA 90:567-571.
85. Davidson, R. M., Shajenko, L., and Donta, T. S. 1994. Amyloid beta-peptide (A beta P) potentiates a nimodipine-sensitive L-type barium conductance in N1E-115 neuroblastoma cells. Brain Res. 643:324-327.
86. Pollard, H. B., Arispe, N., and Rojas, E. 1995. Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Cell Mol. Neurobiol. 15:513-526.
87. Hirakura, Y., Lin, M. C., and Kagan, B. L. 1999. Alzheimer amyloid abetal-42 channels: Effects of solvent, pH, and Congo Red. J. Neurosci. Res. 57:458-466.
88. Lin, H., Zhu, Y. J., and Lal, R. 1999. Amyloid beta protein (1-40) forms calcium-permeable, Zn2+-sensitive channel in reconstituted lipid vesicles. Biochemistry 38:11189-11196.
89. Harkany, T., Abraham, I., Konya, C., Nyakas, C., Zarandi, M., Penke, B., and Luiten, P. G. 2000. Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev. Neurosci. 11:329-382.
90. Harkany, T., Abraham, I., Timmerman, W., Laskay, G., Toth, B., Sasvari, M., Konya, C., Sebens, J. B., Korf, J., Nyakas, C., Zarandi, M., Soos, K., Penke, B., and Luiten, P. G. 2000. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur. J. Neurosci. 12:2735-2745.
91. Ishii, K., Muelhauser, F., Liebl, U., Picard, M., Kuhl, S., Penke, B., Bayer, T., Wiessler, M., Hennerici, M., Beyreuther, K., Hartmann, T., and Fassbender, K. 2000. Subacute NO generation induced by Alzheimer's beta-amyloid in the living brain: Reversal by inhibition of the inducible NO synthase. FASEB J. 14:1485-1489.
92. Perry, E. K., Gibson, P. H., Blessed, G., Perry, R. H., and Tomlinson, B. E. 1977. Neurotransmitter enzyme abnormalities in senile dementia: Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. 34:247-265.
93. Perry, E. K., Perry, R. H., Blessed, G., and Tomlinson, B. E. 1977. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1:189.
94. Sims, N. R., Bowen, D. M., and Davison, A. N. 1981. [14C]Acetylcholine synthesis and carbon dioxide production from [U-14C]glucose by tissue prisms from human neocortex. Biochem. J. 196:867-876.
95. Bartus, R. T., Dean, R. L. 3rd, Beer, B., and Lippa, A. S. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-414.
96. Palmer, A. M. and Gershon, S. 1990. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 4:2745-2752.
97. Francis, P. T., Palmer, A. M., Snape, M., and Wilcock, G. K. 1999. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J. Neurol. Neurosurg. Psychiatry 66:137-147.
98. Kar, S., Issa, A. M., Seto, D., Auld, D. S., Collier, B., and Quirion, R. 1998. Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J. Neurochem. 70:2179-2187.
99. Kar, S., Seto, D., Gaudreau, P., and Quirion, R. 1996. Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J. Neurosci. 16:1034-1040.
100. Auld, D. S., Kar, S., and Quirion, R. 1998. Beta-amyloid peptides as direct cholinergic neuromodulators: A missing link? Trends Neurosci. 21:43-49.
101. Vaucher, E., Aumont, N., Pearson, D., Rowe, W., Poirier, J., and Kar, S. 2001. Amyloid beta peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively-impaired and -unimpaired rats. J. Chem. Neuroanat. 21:323-329.
102. Wang, H. Y., Lee, D. H., D'Andrea, M. R., Peterson, P. A., Shank, R. P., and Reitz, A. B. 2000. Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity: Implications for Alzheimer's disease pathology. J. Biol. Chem. 275:5626-5632.
103. Wang, H. Y., Lee, D. H., Davis, C. B., and Shank, R. P. 2000. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J. Neurochem. 75:1155-1161.
104. Wang, H. Y., D'Andrea, M. R., and Nagele, R. G. 2002. Cerebellar diffuse amyloid plaques are derived from dendritic Abeta42 accumulations in Purkinje cells. Neurobiol. Aging 23:213-223.
105. Hoshi, M., Takashima, A., Noguchi, K., Murayama, M., Sato, M., Kondo, S., Saitoh, Y., Ishiguro, K., Hoshino, T., and Imahori, K. 1996. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc. Natl. Acad. Sci. USA 93:2719-2723.
106. Hoshi, M., Takashima, A., Murayama, M., Yasutake, K., Yoshida, N., Ishiguro, K., Hoshino, T., and Imahori, K. 1997. Nontoxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis: Possible role in cholinergic dysfunction in Alzheimer's disease. J. Biol. Chem. 272:2038-2041.
107. Pedersen, W. A., Kloczewiak, M. A., and Blusztajn, J. K. 1996. Amyloid beta-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci. USA 93:8068-8071.
108. Erickson, J. D., Varoqui, H., Schafer, M. K., Modi, W., Diebler, M. F., Weihe, E., Rand, J., Eiden, L. E., Bonner, T. I., and Usdin, T. B. 1994. Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. J. Biol. Chem. 269:21929-21932.
109. Berrard, S., Varoqui, H., Cervini, R., Israel, M., Mallet, J., and Diebler, M. F. 1995. Coregulation of two embedded gene products, choline acetyltransferase and the vesicular acetylcholine transporter. J. Neurochem. 65:939-942.
110. Varoqui, H., Meunier, F. M., Meunier, F. A., Molgo, J., Berrard, S., Cervini, R., Mallet, J., Israel, M., and Diebler, M. F. 1996. Expression of the vesicular acetylcholine transporter in mammalian cells. Prog. Brain Res. 109:83-95.
111. Pedersen, W. A. and Blusztajn, J. K. 1997. Characterization of the acetylcholine-reducing effect of the amyloid-beta peptide in mouse SN56 cells. Neurosci. Lett. 239:77-80.
112. Diebler, M. F., Tomasi, M., Meunier, F. M., Israel, M., and Dolezal, V. 1998. Influence of retinoic acid and of cyclic AMP on the expression of choline acetyltransferase and of vesicular acetylcholine transporter in NG108-15 cells. J. Physiol. (Paris) 92:379-384.
113. Dolezal, V., Castell, X., Tomasi, M., and Diebler, M. F. 2001. Stimuli that induce a cholinergic neuronal phenotype of NG108-15 cells upregulate ChAT and VAChT mRNAs but fail to increase VAChT protein. Brain Res. Bull. 54:363-373.
114. Dolezal, V., Lisa, V., Diebler, M. F., Kasparova, J., and Tuček, S. 2001. Differentiation of NG108-15 cells induced by the combined presence of dbcAMP and dexamethasone brings about the expression of N and P/Q types of calcium channels and the inhibitory influence of muscarinic receptors on calcium influx. Brain Res. 910:134-141.
115. Castell, X., Diebler, M. F., Tomasi, M., Bigari, C., De Gois, S., Berrard, S., Mallet, J., Israel, M., and Dolezal, V. 2002. More than one way to toy with ChAT and VAChT. J. Physiol. (Paris) 96:61-72.
116. Kasparova, J., Lisa, V., Tuček, S., and Dolezal, V. 2001. Chronic exposure of NG108-15 cells to amyloid beta peptide (A beta [1-42]) abolishes calcium influx via N-type calcium channels. Neurochem. Res. 26:1079-1084.
117. Rossner, S., Ueberham, U., Schliebs, R., Perez-Polo, J. R., and Bigl, V. 1998. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol. 56:541-569.
118. Lin, L., LeBlanc, C. J., Deacon, T. W., and Isacson, O. 1998. Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system. Neuroreport 9:547-552.
119. Browne, S. E., Lin, L., Mattsson, A., Georgievska, B., and Isacson, O. 2001. Selective antibody-induced cholinergic cell and synapse loss produce sustained hippocampal and cortical hypometabolism with correlated cognitive deficits. Exp. Neurol. 170:36-47.
120. Lin, L., Georgievska, B., Mattsson, A., and Isacson, O. 1999. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc. Natl. Acad. Sci. USA 96:12108-12113.
121. Seo, H., Ferree, A. W., and Isacson, O. 2002. Corticohippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. Eur. J. Neurosci. 15:498-506.
122. Blusztajn, J. K. and Berse, B. 2000. The cholinergic neuronal phenotype in Alzheimer's disease. Metab. Brain Dis. 15:45-64.
123. Granholm, A. C., Sanders, L. A., and Crnic, L. S. 2000. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp. Neurol. 161:647-663.
124. Chen, K. S., Nishimura, M. C., Armanini, M. P., Crowley, C., Spencer, S. D., and Phillips, H. S. 1997. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J. Neurosci. 17:7288-7296.
125. Ruberti, F., Capsoni, S., Comparini, A., Di Daniel, E., Franzot, J., Gonfloni, S., Rossi, G., Berardi, N., and Cattaneo, A. 2000. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J. Neurosci. 20:2589-2601.
126. Capsoni, S., Ugolini, G., Comparini, A., Ruberti, F., Berardi, N., and Cattaneo, A. 2000. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl. Acad. Sci. USA 97:6826-6831.
127. Smith, D. E., Roberts, J., Gage, F. H., and Tuszynski, M. H. 1999. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc. Natl. Acad. Sci. USA 96:10893-10898.
128. Conner, J. M., Darracq, M. A., Roberts, J., and Tuszynski, M. H. 2001. Nontropic actions of neurotrophins: Subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc. Natl. Acad. Sci. USA 98:1941-1946.
129. Rapoport, S. I. 2000. Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97:5696-5698.
130. Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., and Frost, J. 2001. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98:3334-3339.
131. Reiman, E. M., Caselli, R. J., Alexander, G. E., and Chen, K. 2001. Tracking the decline in cerebral glucose utilization in persons and laboratory animals at genetic risk for Alzheimer's disease. Clin. Neurosci. Res. 1:194-206.
132. Niwa, K., Kazama, K., Younkin, S. G., Carlson, G. A., and Iadecola, C. 2002. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9:61-68.
133. Tuček, S. and Cheng, S. C. 1974. Provenance of the acetyl group of acetylcholine and compartmentation of acetyl-CoA and Krebs cycle intermediates in the brain in vivo. J. Neurochem. 22:893-914.
134. Gibson, G. E., Jope, R., and Blass, J. P. 1975. Decreased synthesis of acetylcholine accompanying impaired oxidation of pyruvic acid in rat brain minces. Biochem. J. 148:17-23.
135. Gibson, G. E. and Blass, J. P. 1976. Impaired synthesis of acetylcholine in brain accompanying mild hypoxia and hypoglycemia. J. Neurochem. 27:37-42.
136. Dolezal, V. and Tuček, S. 1981. Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices. J. Neurochem. 36:1323-1330.
137. Tuček, S., Dolezal, V., and Sullivan, A. C. 1981. Inhibition of the synthesis of acetylcholine in rat brain slices by (-)-hydroxycitrate and citrate. J. Neurochem. 36:1331-1337.
138. Dolezal, V. and Tuček, S. 1982. Effects of choline and glucose on atropine-induced alterations of acetylcholine synthesis and content in the caudate nuclei of rats. Brain Res. 240:285-293.
139. Ricny, J., Tuček, S., and Novakova, J. 1992. Acetylcarnitine, carnitine and glucose diminish the effect of muscarinic antagonist quinuclidinyl benzilate on striatal acetylcholine content. Brain Res. 576:215-219.
140. Messier, C. and Gagnon, M. 1996. Glucose regulation and cognitive functions: Relation to Alzheimer's disease and diabetes. Behav. Brain Res. 75:1-11.
141. Ragozzino, M. E., Unick, K. E., and Gold, P. E. 1996. Hippocampal acetylcholine release during memory testing in rats: Augmentation by glucose. Proc. Natl. Acad. Sci. USA 93:4693-4698.